Public Health Rep

13004220PMCnul

Distribution of trace gases with adverse effects on fuel cells

The introduction of fuel cell technology into the field of motor vehicle propulsionenables both a reduction in primary energy consumption and a reduction independence on the primary energy source mineral oil. A major advantage of thispropulsion technology is reduction of greenhouse gas emissions when renewableenergy is used for fuels as hydrogen [Robinius, 2019]. Moreover, fluctuations inelectricity energy supply from renewable sources can be dampened when electricityis efficiently converted and stored as hydrogen.For the competitive application of this technology of fuel cell technology in the field ofvehicle propulsion, however, considerable research is still required in some areas. Inaddition to the necessary cost and weight reduction, this also applies to the long-termstability and robustness of fuel cell stack itself.It is known that fuel cell stacks react to the admixture of harmful gases into the intakecathode air with performance losses, which primarily result from the poisoning of thecatalysts. The effect does not only depend on the total burden of pollutants but on theirpeak concentrations. With this regard there is a need for research into both the effectsof pollutants on fuel stacks and their distribution in the atmosphere.The work presented here was funded by BMWi in the period from December 2014 toNovember 2017 and describes the results of the subproject 03ET6036D, which wascarried out by Forschungszentrum Jülic

Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

WOS: 000454014501235

NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY

22nd Congress of the European-Hematology-Association -- JUN 22-25, 2017 -- Madrid, SPAINWOS: 000404127001176…European Hematol Asso

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

PubMedID: 25231929Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report the experience with brentuximab vedotin as single agent in 58 patients with relapsed or refractory Hodgkin lymphoma. The objective response rate was 63.5 % with 13 complete responders (26.5 %) among 49 patients evaluated at the early phase of treatment (2–5 cycles). Upon treatment prolongation (?6 cycles), 37 patients achieved a final objective response rate of 32.4 % with 21.6 % of complete and 10.8 % of partial response. Overall survival at 12 months was 70.6 %, and progression-free survival at 12 months was 32.8 %. Median overall survival could not be reached and median progression-free survival was 7 months. While the median duration of response was 9 months in the whole cohort, it was 11.5 months in the complete responders. Complete response rates in patients treated with >3 chemotherapy regimens before brentuximab vedotin were significantly lower (p = 0.016). Fourteen patients were subsequently transplanted. In conclusion, brentuximab vedotin provided a bridge to transplantation in approximately one quarter of the patients. The declining response rates during the course of treatment suggest that transplantation should be implemented early during brentuximab vedotin treatment. © 2014, The Author(s)

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

PubMed: 325079112-s2.0-85086129098Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (n = 23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature